Date:4/15/2009

ability is excluded from on-going operations as discussed below and in Q&A answer 5. 2) 2009 Net Earnings Excluding Specified Items excludes an after-tax gain of $505, or $0.32 per share, relating to the derecognition of a contingent liability that was recorded in connection with the conclusion of the TAP joint venture. This was partially offset by $60, or $0.04 per share, relating to costs associated with the acquisition of Advanced Medical Optics (AMO), $41, or $0.02, per share for a litigation settlement and $107, or $0.07 per share, for cost reduction initiatives and costs associated with a delayed product launch. 2008 Net Earnings Excluding Specified Items excludes after-tax charges of $37, or $0.02 per share, for cost reduction initiatives and other, $15, or $0.01 per share, for acquired in-process research & development related to a molecular diagnostic technology investment and $7, or $0.01 per share, for acquisition integration; partially offset by an after-tax gain of $9, or $0.01 per share, on sales of Boston Scientific stock. NOTE: See attached questions and answers section for further explanation of Consolidated Statement of Earnings line items. n/m = Percent change is not meaningful.

Questions & Answers

Q1) What impacted the growth of pharmaceutical sales, including HUMIRA?

A1) International pharmaceutical operational sales increased 12.4 percent, excluding a 12.1 percent negative impact from exchange. Internationally, operational growth for HUMIRA was nearly 50 percent, in line with recent quarters, and in line with our expectations. However, there was a 20-percentage point negative impact of exchange on international HUMIRA sales, which was more unfavorable than our original estimate. Interna
'/>"/>

SOURCE Abbott Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine news :

1. Abbott Initiates U.S. Study of Absolute Pro(TM) Peripheral Stent System for Iliac Artery Disease
2. Abbott Hosts Conference Call for First-Quarter Earnings
3. Abbott Launches VOYAGER(TM) NC Coronary Balloon Catheter
4. Abbott to Present at Cowen Annual Health Care Conference
5. Abbott Announces Required Offer to Repurchase Convertible Senior Subordinated Notes of Its AMO Subsidiary
6. Abbott Completes Acquisition of Advanced Medical Optics
7. Abbott Opens New Pediatric Nutrition Manufacturing Facility in Singapore
8. Abbott Successfully Completes Tender Offer for Shares of Advanced Medical Optics
9. Abbott Receives European Commission Clearance on Acquisition of Advanced Medical Optics
10. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
11. Abbott Acquisition of Advanced Medical Optics Clears U.S. Antitrust Review